Silvia Asuncion Fuertes Marraco

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


26 publications

2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
Shared acute phase traits in effector and memory human CD8 T cells.
Fuertes Marraco S.A., Alpern D., Lofek S., Lourenco J., Bovay A., Maby-El Hajjami H., Delorenzi M., Deplancke B., Speiser D.E., 2022. Current research in immunology, 3 pp. 1-12. Peer-reviewed.
Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses.
Bovay A., Fuertes Marraco S.A., Speiser D.E., 2021/08/03. Human vaccines & immunotherapeutics, 17 (8) pp. 2471-2481. Peer-reviewed.
Early drop of circulating T cells negatively correlates with the protective immune response to Yellow Fever vaccination.
Bovay A., Speiser D.E., Fuertes Marraco S.A., 2020/12/01. Human vaccines & immunotherapeutics, 16 (12) pp. 3103-3110. Peer-reviewed.
Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation.
Pais Ferreira D., Silva J.G., Wyss T., Fuertes Marraco S.A., Scarpellino L., Charmoy M., Maas R., Siddiqui I., Tang L., Joyce J.A. et al., 2020/11/17. Immunity, 53 (5) pp. 985-1000.e11. Peer-reviewed.
Identification of a superagonist variant of the immunodominant Yellow fever virus epitope NS4b214-222 by combinatorial peptide library screening.
Bovay A., Zoete V., Rizkallah P.J., Beck K., Delbreil P., Speiser D.E., Cole D.K., Fuertes Marraco S.A., 2020/09. Molecular immunology, 125 pp. 43-50. Peer-reviewed.
 
Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies.
Bovay A., Nassiri S., Maby-El Hajjami H., Marcos Mondéjar P., Akondy R.S., Ahmed R., Lawson B., Speiser D.E., Fuertes Marraco S.A., 2020/02/24. Vaccine, 38 (9) pp. 2172-2182. Peer-reviewed.
 
Analysis of cancer cell-intrinsic immune regulation in response to CD8+ T cell attack.
Neubert N.J., Tillé L., Martignier C., Fuertes Marraco S.A., Speiser D.E., 2020. Methods in enzymology, 631 pp. 443-466. Peer-reviewed.
LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures.
Gestermann N., Saugy D., Martignier C., Tillé L., Fuertes Marraco S.A., Zettl M., Tirapu I., Speiser D.E., Verdeil G., 2020. Oncoimmunology, 9 (1) p. 1736792. Peer-reviewed.
 
Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly.
Saavedra D., Fuertes S.A., Suárez G.M., González A., Lorenzo-Luaces P., García B., Aznar E., Mazorra Z., Crombet T., Speiser D.E. et al., 2019/09. Experimental gerontology, 124 p. 110633. Peer-reviewed.
 
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Neubert N.J., Schmittnaegel M., Bordry N., Nassiri S., Wald N., Martignier C., Tillé L., Homicsko K., Damsky W., Maby-El Hajjami H. et al., 2018/04/11. Science translational medicine, 10 (436). Peer-reviewed.
T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus.
Bovay A., Zoete V., Dolton G., Bulek A.M., Cole D.K., Rizkallah P.J., Fuller A., Beck K., Michielin O., Speiser D.E. et al., 2018/02. European journal of immunology, 48 (2) pp. 258-272. Peer-reviewed.
 
Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells.
Neubert N.J., Tillé L., Barras D., Soneson C., Baumgaertner P., Rimoldi D., Gfeller D., Delorenzi M., Fuertes Marraco S.A., Speiser D.E., 2017/04/01. Cancer research, 77 (7) pp. 1623-1636. Peer-reviewed.
A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells.
Neubert N.J., Soneson C., Barras D., Baumgaertner P., Rimoldi D., Delorenzi M., Fuertes Marraco S.A., Speiser D.E., 2016/08. Frontiers In Immunology, 7 p. 326. Peer-reviewed.
 
From T cell “exhaustion” to anti-cancer immunity
Verdeil Grégory, Fuertes Marraco Silvia A., Murray Timothy, Speiser Daniel E., 2016/01. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1865 (1) pp. 49-57. Peer-reviewed.
Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.
Murray T., Fuertes Marraco S.A., Baumgaertner P., Bordry N., Cagnon L., Donda A., Romero P., Verdeil G., Speiser D.E., 2016. Frontiers in immunology, 7 p. 573. Peer-reviewed.
Inhibitory Receptors Beyond T Cell Exhaustion.
Fuertes Marraco S.A., Neubert N.J., Verdeil G., Speiser D.E., 2015. Frontiers in Immunology, 6 p. 310. Peer-reviewed.
Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination.
Fuertes Marraco S.A., Soneson C., Cagnon L., Gannon P.O., Allard M., Maillard S.A., Montandon N., Rufer N., Waldvogel S., Delorenzi M. et al., 2015. Science Translational Medicine, 7 (282) pp. 282ra48. Peer-reviewed.
 
TLR3-Mediated CD8+ Dendritic Cell Activation Is Coupled with Establishment of a Cell-Intrinsic Antiviral State.
Széles L., Meissner F., Dunand-Sauthier I., Thelemann C., Hersch M., Singovski S., Haller S., Gobet F., Fuertes Marraco S.A., Mann M. et al., 2015. Journal of Immunology, 195 (3) pp. 1025-1033. Peer-reviewed.
 
Cross-presenting dendritic cells are required for control of Leishmania major infection.
Ashok D., Schuster S., Ronet C., Rosa M., Mack V., Lavanchy C., Marraco S.F., Fasel N., Murphy K.M., Tacchini-Cottier F. et al., 2014. European Journal of Immunology, 44 (5) pp. 1422-1432.
 
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion.
Utzschneider D.T., Legat A., Fuertes Marraco S.A., Carrié L., Luescher I., Speiser D.E., Zehn D., 2013. Nature Immunology, 14 (6) pp. 603-610.
 
A stepwise protocol to coat aAPC beads prevents out-competition of anti-CD3 mAb and consequent experimental artefacts.
Fuertes Marraco S.A., Baumgaertner P., Legat A., Rufer N., Speiser D.E., 2012. Journal of Immunological Methods, 385 (1-2) pp. 90-95.
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.
Baitsch L., Legat A., Barba L., Fuertes Marraco S.A., Rivals J.P., Baumgaertner P., Christiansen-Jucht C., Bouzourene H., Rimoldi D., Pircher H. et al., 2012. PLoS One, 7 (2) pp. e30852.
 
The three main stumbling blocks for anticancer T cells.
Baitsch L., Fuertes-Marraco S.A., Legat A., Meyer C., Speiser D.E., 2012. Trends in Immunology, 33 (7) pp. 364-372.
Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis.
Ives A., Ronet C., Prevel F., Ruzzante G., Fuertes-Marraco S., Schutz F., Zangger H., Revaz-Breton M., Lye L.F., Hickerson S.M. et al., 2011. Science, 331 (6018) pp. 775-778.
Type I interferon drives dendritic cell apoptosis via multiple BH3-only proteins following activation by PolyIC in vivo.
Fuertes Marraco S.A., Scott C.L., Bouillet P., Ives A., Masina S., Vremec D., Jansen E.S., O'Reilly L.A., Schneider P., Fasel N. et al., 2011. PLoS One, 6 (6) pp. e20189.
 
Protease-activated receptor 2 signalling promotes dendritic cell antigen transport and T-cell activation in vivo.
Ramelli G., Fuertes S., Narayan S., Busso N., Acha-Orbea H., So A., 2010. Immunology, 129 (1) pp. 20-27. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University